Live Trading News

Live Trading News — Latest Market Updates

AI

As Claude Writes Claude: Why Your Humanity Is Now Your Greatest Asset

The AI revolution is redefining value — shifting it from knowledge and technical skill to the irreplaceable qualities that make us human.

Anthropic’s own tools are now building Anthropic’s tools. “Claude writing Claude” isn’t marketing hyperbole

Shayne Heffernan4 min read
Research
Quantum
The Quantum Tipping Point
Latest News
AI Is the New Infrastructure of Finance
AI
AI News: Cerebras WSE-3 $CBRS $NVDA
Trending tickers · last 48h
Browse all
$GOOG
1 story100% bull
$NVDA
1 story
$GOOGL
1 story
$MSFT
1 story
$AVGO
1 story
$META
1 story
Newsletter
The daily briefing. In your inbox.
Also reading
Advertisement
KXCO

Shayne Heffernan

See all
Latest News

A Simple Guide to the Travel Rule

The Travel Rule is a major anti-money laundering (AML) regulation that requires crypto companies to share personal information

Shayne Heffernan2 min read
Latest News
Bitcoin is a Buy
Shayne Heffernan
Latest News
Google $GOOG Betting Big on the AI Future
Shayne Heffernan

Stocks

See all
Shayne Heffernan

Anthropic Becomes a $1 Trillion AI Powerhouse

Anthropic has officially crossed the $1 trillion valuation threshold, becoming one of the most valuable private companies in the world.

Shayne Heffernan4 min read
Latest News
The New Look Live Trading News
Shayne Heffernan
Latest News
US Govt Invests in Quantum Computing
Shayne Heffernan

FX

See all
Latest News

Markets, FX, Crypto, AI and Quantum — Monday, May 25, 2026

Shayne Heffernan14 min read

Quantum

See all
Latest News

AI and Quantum Computing Merge: The Next Technological Revolution

AI and Quantum Computing Merge: The Next Technological Revolution $NVDA, $IBM, $GOOGL, $AMZN, $IONQ, $RGTI, $QBTS

Shayne Heffernan5 min read
Research
The Quantum Tipping Point
Johanna Etlis
Research
Quantum Computing 2026: Where We Are, What’s Next
Shayne Heffernan

Longevity

See all
Latest News

Stem Cell News, Parkinson's and Cancer

Stem cell science continues to accelerate in 2026, moving from laboratory promise into early clinical reality.

Shayne Heffernan4 min read
KNIGHTSBRIDGE Insights
Research · Legal & Regulatory · Market Intelligence
Explore →